Cisplatin-5-fluorouracil chemotherapy for advanced inoperable squamous carcinoma of the head and neck

✍ Scribed by Johnson, Jonas T. ;Mayernik, David G. ;Myers, Eugene N. ;Nolan, Teresa A. ;Schramm, Victor L. ;Sigler, Barbara S. ;Wagner, Robin L.

• Publisher: Wiley (John Wiley & Sons)
• Year: 1987
• Weight: 368 KB
• Volume: 9
• Category: Article
• ISSN: 0148-6403
• DOI: 10.1002/hed.2890090606

✦ Synopsis

Patients with locally advanced, inoperable squamous cell carcinoma of the head and neck were offered three courses of cisplatin and 96-h 5-fluorouracil (5-FU) infusion. Subsequent therapy included surgery when feasible, irradiation therapy, and a maintenance program of methotrexate (MTX)-5-FU. Thirty-three patients were evaluated prospectively. Seven patients underwent a single course of chemotherapy. Five patients underwent two courses of chemotherapy. Twenty-one patients underwent three courses of adjuvant chemotherapy. The overall response rate was 48% (16 of 33). Fifteen of 21 patients (76%) receiving three courses of chemotherapy evidenced a response: this included three complete responses (CRs) (9%). No responses were seen in patients receiving only one or two courses of chemotherapy. Among responding patients, the initial favorable response to chemotherapy was apparent after the first course of chemotherapy. Patients who failed to demonstrate any response after two courses of chemotherapy did not respond afler a third course. A significant group of patients fail to respond and should be offered participation in other investigational protocols as they become available.